Last reviewed · How we verify
Clostridium Botulinum A Toxin
At a glance
| Generic name | Clostridium Botulinum A Toxin |
|---|---|
| Also known as | BOTOX, NABOTA |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PHASE3)
- A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU) (PHASE3)
- Effect and Tolerance of Botulinum A Toxin Rectal Injections on Fecal Incontinence (PHASE3)
- A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States (PHASE3)
- Study of Intramuscular Injections of OnabotulinumtoxinA to Assess Change in Disease Activity in Pediatric Participants With Spasticity Associated With Cerebral Palsy
- Evaluate the Efficacy and Safety of DWP712 With Moderate to Severe Glabellar Lines (PHASE3)
- Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy (PHASE2)
- Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clostridium Botulinum A Toxin CI brief — competitive landscape report
- Clostridium Botulinum A Toxin updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI